

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4279044

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SPINIFEX PHARMACEUTICALS PTY LTD	12/02/2015
RECEIVING PARTY DATA	
Name:	Novartis AG
Street Address:	Lichtstrasse 35
City:	Basel
State/Country:	SWITZERLAND
Postal Code:	4056
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13522228
CORRESPONDENCE DATA	
Fax Number:	(973)781-8064
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	862-778-7821
Email:	andrea.jacquin@novartis.com
Correspondent Name:	ANDREA JACQUIN
Address Line 1:	ONE HEALTH PLAZA
Address Line 4:	EAST HANOVER, NEW JERSEY 07936
ATTORNEY DOCKET NUMBER:	PAT057018-US-PCT
NAME OF SUBMITTER:	ANDREA JACQUIN
SIGNATURE:	/Andrea Jacquin/
DATE SIGNED:	02/16/2017
Total Attachments: 4	
source=Assignment Spinifex to Novartis AG_forPAT057018-US-PCT#page1.tif	
source=Assignment Spinifex to Novartis AG_forPAT057018-US-PCT#page2.tif	
source=Assignment Spinifex to Novartis AG_forPAT057018-US-PCT#page3.tif	
source=Assignment Spinifex to Novartis AG_forPAT057018-US-PCT#page4.tif	

ASSIGNMENT

This Assignment Agreement is entered into by and between SPINIFEX PHARMACEUTICALS PTY LTD, Corporate One, Suite G5, 84 Hotham Street, Preston, Victoria 3072, Australia, a company organized under the laws of Australia, and NOVARTIS AG, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, SPINIFEX PHARMACEUTICALS PTY LTD does hereby sell, assign and transfer to NOVARTIS AG and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

SEE ATTACHED SCHEDULE OF APPLICATIONS (SCHEDULE C)

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by SPINIFEX PHARMACEUTICALS PTY LTD if this sale, assignment and transfer had not been made.

SPINIFEX PHARMACEUTICALS PTY LTD hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

SPINIFEX PHARMACEUTICALS PTY LTD hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.



This Assignment is effective as from the earliest priority date as stated above.

Executed this 2nd day of December 2015.

SPINIFEX PHARMACEUTICALS PTY LTD

BY  L.S.
Jim Lynch - Authorized Signatory

BY  L.S.
Annette Cromer, Authorized Signatory


Witness 
Print Name Lauren Ross




Witness
Print Name Christopher Smith


Executed this 2nd day of December 2015.

NOVARTIS AG

BY  L.S.
Maureen McGee, authorized signatory

BY  L.S.
Linda Adams, Authorized Signatory


Witness 
Print Name Lauren Ross


Witness
Print Name Christopher Smith

Schedule C
Foreign Cases - Spinifex

Case Reference	Country	Filing Date	Filing Number	Publication Number	Publication Date	Grant Date	Grant Number
PAT057018-AU-PCT	Australia	19 Jan 2011	2011207104			15 Oct 2015	2011207104
PAT057018-CA-PCT	Canada	19 Jan 2011	2787173				
PAT057018-CN-PCT	China	19 Jan 2011	201180014579.1	102821765	12 Dec 2012		
PAT057018-EP-EPT	European Procedure	19 Jan 2011	11734246.9	EP2525795	28 Nov 2012	21 Oct 2015	EP2525795
PAT057018-HK-FPR	Hong Kong	26 Mar 2013	13103821.4	1176554	02 Aug 2013		
PAT057018-JP-PCT	Japan	19 Jan 2011	2012-549209	2013-517300	16 May 2013		
PAT057018-NZ-PCT	New Zealand	19 Jan 2011	601383			29 Oct 2014	601383
PAT057018-US-PCT	United States of America	19 Jan 2011	13/522228	2013-0131103	23 May 2013	04 Aug 2015	9095597
PAT057018-ZA-PCT	South Africa	19 Jan 2011	2012/05375			25 Sep 2013	2012/05375
PAT057019-NZ-PCTD	New Zealand		708529				
PAT057019-US-DIV03	United States of America	20-Sep-2015	14/859347				